IRF4

Opna Bio Presents Promising Preclinical Data in Multiple Myeloma with OPN-6602 and in Malignant Mesothelioma with OPN-9840 Showing Significant Tumor Growth Inhibition at the American Association of Cancer Research Annual Meeting

Retrieved on: 
星期三, 四月 10, 2024
Research, Venture Capital, Clinical Trials, Professional Services, Biotechnology, Health, Pharmaceutical, Science, Oncology, CREB-binding protein, NF2, Dexamethasone, FDA, MYC, TGI, Cancer, Bone marrow, Abdomen, Multiple myeloma, Mouse, MYB, Mesothelioma, EP300, Streets of Rage, Doctor of Philosophy, IND, Glomus tumor, TEAD, FMRP, Therapy, BRAF, CBP, Thomas Jefferson University, Patient, Neurofibromatosis, Hippopotamus, Neoplasm, Standard of care, AACR, E1A, IRF4

Data were shared at the American Association of Cancer Research (AACR) Annual Meeting, taking place April 5-10, 2024 in San Diego.

Key Points: 
  • Data were shared at the American Association of Cancer Research (AACR) Annual Meeting, taking place April 5-10, 2024 in San Diego.
  • Multiple myeloma is an aggressive blood cancer derived from malignant plasma cells in the bone marrow.
  • "We are excited to begin our Phase 1 study of OPN-6602 in patients with multiple myeloma this summer.
  • Malignant mesothelioma is a rare and aggressive cancer that primarily affects the lining of the lungs or abdomen.

Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results

Retrieved on: 
星期四, 三月 21, 2024
Research, Ovarian cancer, Conference, Survival, AML, Carcinoma, RECIST, Patient, SAN, Multiple myeloma, KRON, Cancer, IRF4, Lung cancer, IND, AACR, Investment, KAT, CDK9, Pharmaceutical industry

SAN MATEO, Calif. and CAMBRIDGE, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today reported recent business progress and fourth-quarter and full-year 2023 financial results.

Key Points: 
  • “In 2023, we made great progress across our portfolio and business.
  • Kronos Bio extended its expected cash runway by a year, into the second half of 2026, through restructurings and resource optimization.
  • Net Loss: Net loss for the fourth quarter of 2023 was $25.3 million, or $0.43 per share, including non-cash stock-based compensation expense of $5.2 million.
  • Net loss for the full-year 2023 was $112.7 million, or $1.95 per share, including non-cash stock-based compensation expense of $25.0 million.

Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting

Retrieved on: 
星期二, 三月 5, 2024
SAN, IRF4, Senior, KRON, Research, Research and development, Adenoid cystic carcinoma, AACR, Molecular biology, Gene expression, Abstract, Multiple myeloma, CDK9, KAT, Development, Cancer, Pharmaceutical industry

SAN MATEO, Calif. and CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that three abstracts have been selected for presentation at the American Association for Cancer Research (AACR) annual meeting, being held from April 5-10, 2024 in San Diego, California.

Key Points: 
  • SAN MATEO, Calif. and CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that three abstracts have been selected for presentation at the American Association for Cancer Research (AACR) annual meeting, being held from April 5-10, 2024 in San Diego, California.
  • “We are excited to present our data at AACR showing that targeting p300’s enzymatic KAT domain can selectively downregulate IRF4, a long sought after transcription factor dependency in multiple myeloma.
  • Although p300 is an essential gene, our data show that through its relationship as a critical IRF4 cofactor, we can achieve selective antiproliferative effects against myeloma cells,” said Charles Lin, Ph.D., Senior Vice President, Research and Development of Kronos Bio.
  • Details for the AACR 2024 abstracts are as follows:
    Title: A dose escalation and cohort expansion study of the CDK9 inhibitor KB-0742 in relapsed, refractory and transcriptionally addicted solid tumors
    Title: KB-0742, an oral highly selective CDK9 inhibitor, demonstrates preclinical activity in transcription factor fusion driven adenoid cystic carcinoma patient-derived models
    Poster Session: Molecular Biology in Clinical Oncology: Characterizing and Modulating Epigenetics and Gene Expression

Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development Candidate

Retrieved on: 
星期一, 十二月 18, 2023
Patient, Map, Downregulation and upregulation, KAT, Kronos, Research, SYK, CDK9, Dana–Farber Cancer Institute, CRH, Disease, Multiple myeloma, SAN, KRON, White noise, Infection, Cancer, IRF4, TRN, AML, Pharmaceutical industry

SAN MATEO, Calif. and CAMBRIDGE, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced an update on its pipeline. After a review of data from the phase 1b portion of its phase 1b/2 trial of lanraplenib in combination with gilteritinib in FLT3-mutated relapsed/refractory acute myeloid leukemia (AML), the Company has decided not to proceed to phase 2. The Company is open to further development of lanraplenib, a SYK inhibitor, with a partner.

Key Points: 
  • The Company is open to further development of lanraplenib, a SYK inhibitor, with a partner.
  • Kronos Bio also announced the designation of a new development candidate, KB-9558, which targets the lysine acetyltransferase (KAT) domain of p300, a critical node of the IRF4 transcription regulatory network (TRN).
  • “Kronos Bio was founded with a clear vision: to tackle the challenge of deregulated transcription, a hallmark of cancer,” said Norbert Bischofberger, Ph.D., president and chief executive officer of Kronos Bio.
  • We look forward to continuing to work with the Kronos Bio team to bring KB-9558 to patients.”
    “We believe that KB-9558 is positively differentiated from compounds targeting other p300 domains,” said Christopher Dinsmore, Ph.D., chief scientific officer of Kronos Bio.

Preclinical Data from Kymera Therapeutics’ Collaborations Demonstrate Therapeutic Potential of STAT3 Degraders in CTCL and IRAKIMiD Combination with BCL-2 Inhibitor in MYD88-Mutant DLBCL at the American Society of Hematology Annual Meeting

Retrieved on: 
星期一, 十二月 12, 2022
NF-κB, Annual report, Security (finance), ASH, Memorial Sloan Kettering Cancer Center, COVID-19, IRF4, B-cell lymphoma, Disease, Safety, Biotechnology, Skin, Cutaneous T cell lymphoma, Boston, Boston Business Journal, Risk, Society, Lymphatic system, Therapy, MDM2, PDX, Immunomodulatory imide drug, CTCL, MYD88, Pathology, Apoptosis, Patient, Science, CDX, STAT3, DLBCL, Vaccine, Pharmaceutical industry, Black Majesty, Medicine, IRAK4

WATERTOWN, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that preclinical data from collaborations for its STAT3 and IRAKIMiD degraders was presented at the American Society of Hematology (ASH) Annual Meeting, taking place from December 10 - 13, 2022 in New Orleans, Louisiana.

Key Points: 
  • The model was used to evaluate the therapeutic potential of one of Kymera’s potent and selective STAT3 heterobifunctional degraders for targeting this difficult-to-treat hematologic malignancy.
  • A single intravenous infusion of a STAT3 degrader led to substantial reduction in STAT3 levels in lymph node T cells, circulating T cells, and skin-resident T cells.
  • These data provide a rationale for selective STAT3 degradation as a therapeutic strategy for T cell malignancies such as CTCL that are associated with constitutive activation of STAT3 signaling.
  • Kymera’s lead STAT3 degrader, KT-333, is currently being evaluated in a Phase 1 clinical trial in liquid and solid tumors, including CTCL.

CellCentric presents early clinical data at ASH: inobrodib (CCS1477), first in class p300/CBP bromodomain inhibitor treating relapsed refractory multiple myeloma

Retrieved on: 
星期一, 十二月 12, 2022
R.J. Corman Railroad Group, Oncology, Hematology, Serum, CBP, Internal medicine, PR, Multiple myeloma, Drug discovery, Society, Endpoint security, Mayo Clinic College of Medicine and Science, Patient, DNA, Mayo Clinic, University of Cambridge, Cancer, Dana–Farber Cancer Institute, Oncogene, Research, Gurdon Institute, Partial-response maximum-likelihood, Takeda Pharmaceutical Company, Division, Disease, NHS foundation trust, MCRPC, Dexamethasone, RRMM, MYC, The Christie NHS Foundation Trust, Lymphatic system, Translation, University, IRF4, University of Manchester, Harvard Medical School, Gene, Toxic leukoencephalopathy, ASH, Cancer research, Medical imaging, Pharmaceutical industry, Medicine

Taken together, these findings provide clear encouragement for the further clinical development of this first in class drug."

Key Points: 
  • Taken together, these findings provide clear encouragement for the further clinical development of this first in class drug."
  • Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational
    CellCentric has developed inobrodib from concept through to clinical trials.
  • It is an oral, first in class small molecule inhibitor drug that targets twin cancer gene regulators p300 and CBP.
  • The company actively pursued multiple drug discovery programmes before prioritising p300/CBP inhibition and inobrodib.

CellCentric presents early clinical data at ASH: inobrodib (CCS1477), first in class p300/CBP bromodomain inhibitor treating relapsed refractory multiple myeloma

Retrieved on: 
星期一, 十二月 12, 2022
R.J. Corman Railroad Group, Oncology, Hematology, Serum, CBP, Internal medicine, PR, Multiple myeloma, Drug discovery, Society, Endpoint security, Mayo Clinic College of Medicine and Science, Patient, DNA, Mayo Clinic, University of Cambridge, Cancer, Dana–Farber Cancer Institute, Oncogene, Research, Gurdon Institute, Partial-response maximum-likelihood, Takeda Pharmaceutical Company, Division, Disease, NHS foundation trust, MCRPC, Dexamethasone, RRMM, MYC, The Christie NHS Foundation Trust, Lymphatic system, Translation, University, IRF4, University of Manchester, Harvard Medical School, Gene, Toxic leukoencephalopathy, ASH, Cancer research, Medical imaging, Pharmaceutical industry, Medicine

Taken together, these findings provide clear encouragement for the further clinical development of this first in class drug."

Key Points: 
  • Taken together, these findings provide clear encouragement for the further clinical development of this first in class drug."
  • Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational
    CellCentric has developed inobrodib from concept through to clinical trials.
  • It is an oral, first in class small molecule inhibitor drug that targets twin cancer gene regulators p300 and CBP.
  • The company actively pursued multiple drug discovery programmes before prioritising p300/CBP inhibition and inobrodib.

Scientists Map Networks of Disease-Associated Immune Genes

Retrieved on: 
星期一, 七月 11, 2022
Burroughs Wellcome Fund, Blood, IRF4, Nature Genetics, Health, CTLA4, Biology, Stanford Center for Computers and the Law, National Cancer Research Institute, Genetics, IL2RA, Stanford School, Stanford University School of Medicine, Transcription factor, Walter Sinnott-Armstrong, Disease, University of California, San Francisco, UCSF, Pritchard, Multiple sclerosis, Biohub, Doctor of Philosophy, Feedback, Gladstone Institutes, Map, Computation, University, Marson, Infection, National, National Institutes of Health, Cell, Risk, Multimedia, San Francisco Bay Area, Gene, Autoimmune disease, Time, CRISPR, Factor X, Lupus, Technology, International Chinese Language Program, Rheumatoid arthritis, Cancer Research Institute, Immune system, Biomedical Research, MD, NASA, Protein, SAN, Vaccine, Instrumentation, Pharmaceutical industry

SAN FRANCISCO, July 11, 2022 /PRNewswire/ -- Using new technologies to study thousands of genes simultaneously within immune cells, researchers at Gladstone Institutes, UC San Francisco (UCSF), and Stanford School of Medicine have created the most detailed map yet of how complex networks of genes function together. The new insights into how these genes relate to each other shed light on both the basic drivers of immune cell function and on immune diseases.

Key Points: 
  • The new insights into how these genes relate to each other shed light on both the basic drivers of immune cell function and on immune diseases.
  • Scientists represent these connections among proteins and genes as networks that look somewhat like a subway map.
  • Mapping these networks is important because they can help explain why mutations in two different immune genes might lead to the same disease, or how a drug might have an impact on many immune proteins at once.
  • In the past, scientists have mapped out a part of these networks by removing the gene for each protein, one at a time, and studying the impact on other genes and proteins, as well as on immune cells' overall function.

 InnoCare Announces Approval of Clinical Trial of Novel Targeted Protein Degrader ICP-490 in China

Retrieved on: 
星期四, 七月 7, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, National Medical Products Administration, DLBCL, Patient, CEO, Multiple myeloma, Investigational New Drug, Cancer, Follicular lymphoma, B-cell lymphoma, Degenerative disease, Non-Hodgkin lymphoma, IRF4, Ubiquitin, B cell, Anemia, Lymphatic system, Factor X, Acute kidney injury, NHL, Clinical trial, Hypercalcaemia, IND, NMPA, HKEX, MM, Bone marrow, Pharmaceutical industry

It also has immunomodulatory effects by enhancing the function of effector T cells, resulting from Ikaros and Aiolos degradation and the degradation-mediated releasing of interleukin IL-2.

Key Points: 
  • It also has immunomodulatory effects by enhancing the function of effector T cells, resulting from Ikaros and Aiolos degradation and the degradation-mediated releasing of interleukin IL-2.
  • Dr. Jasmine Cui, the co-founder, Chairwoman and CEO of InnoCare said, InnoCare has built a strong pipeline in the field of blood tumor.
  • With the approval of ICP-490 for clinical trials, InnoCare will further strengthen its blood tumor pipeline and aim to provide better treatment options for those patients in China and around the world.
  • We strategically focus on liquid cancer, solid tumors, and autoimmune diseases with high unmet medical needs in China and worldwide.

Flamingo Therapeutics Expands Alliance with Ionis Pharmaceuticals to Develop RNA-targeted Therapies for Oncology

Retrieved on: 
星期四, 九月 9, 2021

LEUVEN, Belgium, Sept. 9, 2021 /PRNewswire/--Flamingo Therapeutics, Inc., a biotechnology company pioneering RNA-targeting therapies in oncology, today announced that it has entered into an agreement with Ionis Pharmaceuticals to develop RNA-targeted therapies to treat various forms of cancer.

Key Points: 
  • LEUVEN, Belgium, Sept. 9, 2021 /PRNewswire/--Flamingo Therapeutics, Inc., a biotechnology company pioneering RNA-targeting therapies in oncology, today announced that it has entered into an agreement with Ionis Pharmaceuticals to develop RNA-targeted therapies to treat various forms of cancer.
  • This alliance is an expansion of an existing collaboration with Ionis on the FLAME discovery engine, following Flamingo's Series A financing in 2020.
  • In connection with the alliance, Rob MacLeod, Ph.D.,VP, Oncology Research & Development of Ionis, will serve as Chief Scientific Officer of Flamingo.
  • Flamingo has a discovery alliance with Ionis Pharmaceuticals and is supported by well-known biotechnology investors Kurma Partners and PMV.